Bavarian Nordic sees soaring revenue as pox vaccine orders mount – ET HealthWorld


Bavarian Nordic sees soaring revenue as pox vaccine orders mount

Bengaluru: Danish pharma company Bavarian Nordic said on Wednesday it expects its revenue and core profit to grow significantly in 2023, owing to mounting orders for pox vaccines.

The company sees revenue for the year of around 6.00 billion Danish crowns ($862.99 million) against 3.15 billion crowns expected for 2022 with some 4.40 billion crowns coming from mpox and smallpox vaccined contracts alone.

Earnings before interest, taxes, depreciation and amortization (EBITDA) in 2023 are expected to reach 2.20 billion crowns against 329 million crowns seen for 2022.

Follow and connect with us on , Facebook, Linkedin, Youtube





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *